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Abstract 
In the present work, a workflow on the development of a continuous protein crystallisation is 
introduced, with lysozyme as a model protein, from micro L screening experiments, to small 
scale batch crystallisation experiments in a shaking crystallisation platform, and to batch and 
continuous crystallisation experiments in an oscillatory flow platform. The lysozyme 
crystallisation investigated were for a concentration range from 30 to 100 mg/mL, shaking 
conditions from 100 to 200 rpm in the batch shaking crystallisation platform, and oscillatory 
conditions with amplitude (𝑥𝑥0) from 5 to 30 mm and frequency (𝑓𝑓) from 0.1 to 1.0 Hz in the 
batch oscillatory flow crystallisation platform. We propose the use of the Reynold’s number 
(𝑅𝑅𝑒𝑒) for scaling up of the process from the shaking batch to the continuous oscillatory flow 
platform. Additionally, it is shown that the nucleation rate increased with increase in 
concentration of initial lysozyme solution, or increase in shear rate, inducing smaller size of 
lysozyme crystals. These indicate that continuous crystallisation platforms may offer 
advantages to the downstream bioprocessing of proteins.  
 
Introduction 
There is an acceleration in the development of biopharmaceuticals as next generation 
therapeutics, with sales of biopharmaceuticals and biotherapy from only Humira, Remicade, 
and Enbrel exceeding $18 billion in US in 2015. Protein therapy is expected to create about 
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$250 billion in savings over the next 10 years.1 Manufacturing biopharmaceuticals in a cost 
effective and reliable route becomes a major industrial challenge for meeting the rapidly 
growing demands of protein-based medicines. Crystallisation of proteins as one-step operation 
is more efficient, leading to higher purity protein than conventional purification techniques, 
such as chromatography.2–4 Protein crystals are more stable and are advantageous in terms of 
storage, formulation and drug delivery.2,5    
 
The research for protein crystallisation traditionally focuses on the growth of single protein 
crystals for determination of their structures by crystallography,6 which can reveal important 
information on their biological functions.7 Crystallisation experiments of hanging drop and 
sitting drop in scales of hundreds of nL to several μL with high-through screening are used to 
find the crystallisation conditions of a target protein.8–10 The screening of protein crystallisation 
identifies suitable buffer solutions for stabilising the protein molecules, suitable precipitants for 
generating nucleation of the protein. However, protein crystallisation remains a challenge due 
to their huge and complex 3D molecular structure as well as purity of the protein from broth 
solution.11 The crystallisation of protein is also influenced by pH,12 ionic strength,13 
concentration of PEG,14 magnetic fields15 and etc. Successful screening experiments are a 
starting point for the batch protein crystallisation, which offer the suitable pH, PEG, salt for 
growing crystals, and the basic understanding of the supersaturations and growth rates. 
However, the kinetics of screening crystallisation condition can be totally different with the 
batch crystallisation condition, since the concentration of protein in the droplet during vapour 
diffusion changes over time. A limited number of work have reported the scaling up of 
crystallisations for different proteins: lysozyme and lipase with volume of 5 mL – 1 L,16 FabC225 
with 5 mL - 100 mL in unbaffled stirred tank,17 lysozyme and mAb01 product with 150 mL in 
product removal tank18 and ovalbumin in bottle with 250 mL.19  
 
Continuous manufacturing connecting reaction, crystallisation and formulation have been 
documented to improve the efficiency of pharmaceutical manufacturing,20,21 drawing interests 
from both the academics and pharmaceutical industrials. Continuous crystallisation platforms, 
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like mixed-suspension mixed-product-removal (MSMPR), batch moving fluid oscillatory baffled 
crystallizer (MFOBC), continuous oscillatory flow crystallizers (COFC)22,23 and etc. have been 
developed and applied to many small organic pharmaceuticals. The knowledge of continuous 
oscillatory flow crystallisation on organic pharmaceutical molecules also contributes to the 
develop and design of protein crystallisation process, i.e. crystallisation of insulin in oscillatory 
flow glass capillaries3 and crystallisation of lysozyme in meso oscillatory flow reactor.24 
However, to our knowledge, there is neither continuous oscillatory flow crystallisation research 
reported for any protein nor the development workflow for a process from shaking batch to 
continuous oscillatory flow crystallisation. This work will introduce a basic workflow for batch to 
continuous crystallisation of protein, for scaling up from μL to orders of magnitude larger scale. 
The Reynolds numbers, crystallisation time and the resident time, as key references, are 
compared among several crystallisation platforms. Lysozyme (as a model protein) was used to 
demonstrate this crystallisation workflow from batch shaking tube/crystalliser (BSC) to batch 
oscillatory flow tube/crystalliser (BOFC) to continuous oscillatory flow tube/crystalliser (COFC), 
investigated at concentrations from 30 to 100 mg/mL, with shaking conditions from 100 to 200 
rpm, and oscillatory conditions with amplitude (𝑥𝑥0) from 5 to 30 mm and frequency (𝑓𝑓) from 
0.1 to 1.0 Hz. The size and quality of lysozyme crystals (product) obtained during the steady 
state in continuously crystallisation experiment were compared with starting (feed) materials. 
 
Experimental  
Lysozyme from chicken egg white (purity ≥90 %, ≥40,000 units/mg protein), sodium acetate 
(purity > 99%), sodium chloride (purity > 99.5%) and glacial acetic acid (purity > 99.5 %) were 
purchased from Sigma Aldrich and used without further purification. Distilled water was used.  
 
Buffer solution was prepared as 0.1 M sodium acetate in deionized water at pH 4.8 adjusted by 
addition of acetic acid. The lysozyme solutions with concentration of 30 to 100 mg/mL were 
prepared by dissolving lysozyme in a sodium acetate buffer solution, and the precipitant 
solution was 100 mg/mL NaCl in buffer solution. All solutions were filtered with a 0.2 μm filter. 
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The crystallisation experiments were performed in platforms of batch shaking tube/crystalliser 
(BSC) and batch and continuous oscillatory flow tube/crystalliser (BOFC and COFC) respectively. 
The crystallisation solutions were mixed with 1:1 volume ratio of the lysozyme solution 30 - 100 
mg/mL and the precipitant solution. 2 to 4 experiments were repeated for each crystallisation 
condition at 20 ± 1 °C.  
Table 1 Lysozyme crystallisation conditions for various platforms 
Exp. Platform 𝐶𝐶  
(mg/mL) 
ω  
(rpm) 
𝑓𝑓  
(Hz) 
𝑥𝑥0 
(mm) 
𝑄𝑄 
(mL/min) 
No. 
of Exp. 
𝑅𝑅𝑒𝑒  
I BSC 50-90  100-200 - - - 18 45-90  
II BOFC  30-100  0.5 20 - 16* 212  
III* BOFC  50  0.1-1 20 - 16* 42-424  
IV* BOFC  50  0.5 5-30 - 13* 53-318  
V COFC 50  0.5 20 0.1 2 ~212  
*The numbers of these three experiments include the same experiments at 0.5 Hz - 20 mm with 
𝐶𝐶 at 50 mg/mL. 𝐶𝐶: initial concentration of lysozyme solution.  
 
 
Figure 1 Schematic of the COFC set-up. Protein and precipitation solutions were feed from two 
syringe pumps, respectively, and the oscillatory flow was generated by another syringe pump. 
In the BSC experiments, 0.5 mL crystallisation solution in each Eppendorf tube was shaken on 
an orbital shaking plate at 100, 150 and 200 rpm. A PVC tube of 27 cm length and 3 mm internal 
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diameter was used in BOFC, with volume about 2 mL, which was connected to the pumps 
shown in Figure 1. The crystallisation solutions in the PVC tube were oscillated with, 𝑥𝑥0, 5 - 30 
mm, and, 𝑓𝑓, 0.1 - 1.0 Hz, shown in Table 1. In the COFC, crystallisation solutions were mixed by 
connecting two syringe pumps (Figure 1), which were filled with the protein and precipitant 
solutions separately. The solutions were pumped with a net flow rate of 0.1 mL/min in total to a 
PVC tube (volume about 20 mL) of about 300 cm length and 3 mm internal diameter. The 
oscillations were generated by another one or two syringe pumps with, 𝑥𝑥0, 20 mm, and, 𝑓𝑓, 0.5 
Hz. Samples of 2 μL were taken from crystallisation solution every 15 or 30 minutes up to 180 
and 360 minutes in batch and continuous crystallisation experiments, respectively. 
Concentrations of the samples were determined by Nanodrop One (Thermo Scientific) and off-
line images were recorded by a microscope (Olympus cx41) connected to a digital camera 
(Moticam 5.0MP).  
 
The crystallisation solution in COFC was continuously pumped out and recovered on a 45 mm 
diameter filter with a filtration paper attached (Whatman® qualitative filter paper, Grade 4, 
circles). The funnel was connected to a continuously running vacuum pump. The collected 
crystal samples were dried in a fume hood at room temperature for two days. Crystal samples 
were then dispersed in pure ethanol, placed in a sonication water bath (Cole-Parmer 3 Liter 
Ultrasonic) with a frequency output 40 kHz for 30 s at room temperature, prior to 
determination of size distribution using a Malvern 2000. 
 
The bioactivity of lysozyme crystals (product) obtained was tested with the Lysozyme Activity 
Kit (Sigma Aldrich), based on the cell disruption (lysis) of Micrococcus lysodeikticus cells 
(substrate) from an initial concentration of approximately 0.18 mg/mL. After addition of the the 
lysozyme solution into the substrate solution, the reaction was recorded by measuring the 
decrease in absorbance at 450 nm with Nanodrop One (Thermo Scientific) during incubation.25 
 
Workflow 
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Figure 2 shows the proposed workflow for the development of a continuous oscillatory flow 
protein crystallisation process, from screening to scale-ups in batch and continuous modes.  
 
Stage I – Screening (µL scale) 
In order to develop the continuous crystallisation process for a target protein, it is important to 
know the crystallisation conditions.26–29 If they are not reported in literature, high-throughput 
screening experiments need to be performed, where protein crystallisation takes place in μL 
droplets under quiescent condition. The screening process typically starts with the vapour 
diffusion method, but it is also possible to start the microbatch method directly.10  
 
The key crystallisation conditions include temperature, pH, protein concentration and additive 
concentrations.30 Extreme values of these variables should be avoided to minimise any 
potential irreversible denaturation of proteins. The efficiency of screening can be improved by 
the incomplete factorial and sparse matrix methods, which significantly reduces the number of 
screening conditions required for identifying the suitable conditions.31–33 Successful screening 
conditions can be used for constructing the protein phase diagram, where the precipitation and 
nucleation zone can be detected by the appearance of precipitate and crystal, while the growth 
zone can be detected by the microseed matrix screening method.34–38 The favourable 
crystallisation conditions can be further optimised to obtain crystals of desired morphology and 
size.  
 
Stage II – transferring to batch process (mL scale) 
With the optimised crystallisation conditions from the screening step, the crystallisation can be 
first scaled up in a ~1 mL tube, where mixing can be generated by shaking or stirring (magnetic 
stirrer). The mass transfer in the scaled-up experiments with mixing is significantly different 
from the quiescent screening experiments. Firstly, shear has been reported to accelerate the 
nucleation of proteins such as ferritin, apoferritin, lysozyme and insulin,3,39–41 as well as small 
organic molecules.23,42 On the other side, shear may narrow the metastable zone width24,43 and 
drive the crystallisation solution into the precipitation zone,6 where salt crystals formed or 
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proteins are polymerized or denaturated.44 As scaling up to this small batch crystallisation, the 
concentrations can be tracked, and the size of crystals can be analyzed under microscope 
during the crystallisation process, which provide the initial information of the kinetics for the 
process design. Once one batch experiment is successful, the crystallisation conditions such as 
the shaking frequency or the stirring rate, as well as temperature, pH and protein 
concentrations can be optimised to desired targets of induction time and residence time.  
 
Stage III – transferring to semi-continuous process (mL scale) 
The optimised shaking batch experiments can then be transferred to the oscillatory flow set-up 
that has a small volume of 2 – 3 mL. Some large-scale protein crystallisation have been 
performed in stirred tank crystallisers due to their ease of control and operation,17,19,45–47 but 
tubular crystallisers have attracted the attention of researchers in recent years, due to the 
ability to achieve homogeneous mixing and hence narrower crystal size distribution in these 
crystallisers.3,48,49,50 Tubular crystallisers can be operated in direct or oscillatory flow. In the first 
case, mixing can be enhanced by increasing the flow velocity or by introducing bubbles,39,40 but 
it might not be suitable for proteins that are sensitive to shear stress and exposure to gas.3 The 
oscillatory flow configuration avoids the problems of its direct flow counterpart as mixing is 
generated by the periodic change of flow direction and a lower flow velocity can be used.3,24       
 
The extent of shaking is useful for determining the frequency of oscillation with reference to 
the Reynold’s number. The batch oscillatory flow crystallisation experiments can provide more 
accurate kinetics of the nucleation and crystallisation parameters for the process control of the 
continuous crystallisation. There are other factors that can be considered to improve the 
protein crystallisation, such as seeding,19 surface chemistry,51 and porous templates52 which 
have been reported for lysozyme, thaumatin, trypsin, catalase, concanavalin A and ferritin.4,52–
54 All these factors, as well as baffled oscillatory crystalliser,20,23 can be optimised at this stage 
for the introduction of a more efficient crystallisation process, prior to scaling up to the COFC.  
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Figure 2 Workflow for the development of continuous oscillatory protein crystallisation. 
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Stage IV – transferring to continuous process (mL-L scale) 
In an oscillatory flow system, the continuous operation involves the continuous introduction of 
protein and precipitant into the system and the continuous removal of slurry through the 
outlet. The final step is to demonstrate the continuous crystallisation, which requires long time 
running. The transfer from the semi-continuous crystallisation to the continuous process may 
be robust at the initial continuous process, due to the similarity of the mixing conditions. 
However, the risks may dramatically increase due to long time running. Many challenges have 
been reported in previous developments of small organic molecules,20,55,56 such as leaking and 
fouling due to the long time running time. As in protein crystallisation, the residence time (slow 
growth rate)57 and secondary nucleation (protein crystal is more fragile)44 are also challenges. 
The temperature changes along the oscillatory flow can be optimised, and the strategy of 
adding seeding or templates along the flow need to be considered. 
 
Results and discussions 
Batch shaking crystallisation 
The target was to achieve a three-hour residence time, with a sufficient reduction in 
concentration to achieve an efficient yield. Based on the previous literatures of lysozyme 
crystallisation for buffer, pH and precipitant,24,40,58,59 two different initial concentrations; 50 and 
90 mg/mL, with three stirring rates, 100, 150 and 200 rpm were investigated in BSC. Figure 3 
show that the concentrations dropped to a relative low level during the first 180 min under 
these experimental conditions.  
 
The crystallisation solutions in BSC with 90 mg/mL lysozyme solution all nucleated within 30 
min, while the nucleation with 50 mg/mL lysozyme solution occurred at about 30 - 60 min with 
all three shaking rates, shown in Figure 3. At 120-180 min, the crystallisation solutions with 90 
mg/mL lysozyme solution were overall lower than those with 50 mg/mL lysozyme solution. The 
lysozyme concentration of crystallisation solution at 180 min indicated that the with 50 mg/mL 
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lysozyme solution needed a longer time to reach equilibrium state than those with 90 mg/mL 
lysozyme solution. 
 
 
Figure 3 Lysozyme concentrations of crystallisation solutions after mixing in BSC with shaking 
rate of 100, 150 and 200 rpm, with initial lysozyme solutions at 50 mg/mL (shaking at 100 and 
200 rpm) and 90 mg/mL (shaking at 100 and 200 rpm). 
Crystal images in Figure 3 show that the crystals obtained from the high concentration 
lysozyme solutions were smaller than those from the low concentration lysozyme solution, 
indicating a higher nucleation rate and hence a larger number of crystals generated. 
Crystallisation solutions with 50 mg/mL lysozyme solution nucleated at about 100 min with the 
shaking rate of 100 rpm, while at about 30 min with shaking rate at 200 rpm. The faster the 
shaking rate was, the faster the decrease in concentration of crystallisation solution and smaller 
crystals were obtained (Figure 3) for lysozyme solutions of the same concentration. This could 
be a result of the higher homogeneous nucleation rate or secondary nucleation rate due to a 
higher shear rate, which is in consistence with the literatures.23,60 The crystals with the best 
shape were obtained in the lysozyme solution of low concentration 50 mg/mL with the low 
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shaking rate at 100 rpm in BSC (Figure 3). The higher shaking rates or higher concentrations 
resulted in smaller crystals, which indicated the number of crystals would be higher, and the 
edge of crystals became not obvious, i.e. irregular shape of the crystals.  
 
Reynolds number, 𝑅𝑅𝑒𝑒, is used for defining the platforms and this parameter is used to transfer 
conditions from the BSC to the BOFC. For the shaking flasks/bioreactor and the oscillation 
crystalliser, 𝑅𝑅𝑒𝑒[𝑠𝑠ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎] and 𝑅𝑅𝑒𝑒[oscillation] can be estimated by Eqn. 161,62 and Eqn. 2,20,63,64 
respectively,    
𝑅𝑅𝑒𝑒[shaking] = 𝑛𝑛𝑛𝑛𝑑𝑑𝑆𝑆𝑆𝑆𝑆𝑆2𝜇𝜇                                                                           (1)  𝑅𝑅𝑒𝑒[oscillation] = 2𝜋𝜋𝜋𝜋𝑥𝑥0𝑛𝑛𝑑𝑑𝑂𝑂𝑂𝑂𝑆𝑆𝜇𝜇                                                                    (2) 
where 𝜌𝜌 is the density of the liquid, which is assumed to be same as the water. 𝑎𝑎 is the shaking 
frequency with unit of Hz, 𝑑𝑑𝑆𝑆𝑆𝑆𝑆𝑆  and 𝑑𝑑𝑂𝑂𝑂𝑂𝑆𝑆  are the inner-diameter of the shaking tube and 
oscillatory flow tube, respectively, and 𝜇𝜇 is dynamic fluid viscosity with unit of mPa/s. 
 
Figure 4 Lysozyme concentration for BOFC with 𝑥𝑥0  at 20 mm and 𝑓𝑓  at 0.5 Hz. Initial 
concentration of lysozyme solution was 30, 50, 70, 90 and 100 mg/mL. 
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The 𝑅𝑅𝑒𝑒 under different experimental conditions of BSC and BOFC are shown in Table 1. Based 
on the crystal shapes and the concentration profiles in BSC, the 50 mg/mL lysozyme solution 
with shaking rate of 150 - 200 rpm were suitable experimental conditions for the process to 
transfer to BOFC. In this work, to further understand the influence of the oscillatory flow and 
concentration on the crystallisation of lysozyme, a larger range of shear rates (42-424 s-1) and 
concentrations (30-100 mg/mL) of lysozyme solution were investigated in BOFC.   
  
Batch oscillatory flow crystallisation 
The concentration of the crystallisation solution, shown in Figure 4, at 180 min with high 
concentration of lysozyme solution were lower than those with low concentration of lysozyme 
solution, which were in agreement with the BSC experimental results, indicating that the crystal 
growth was relatively slow and highly dependent on the particle number after the nucleation. 
The best shaped lysozyme crystal was obtained at 50 mg/mL in BOFC, and higher lysozyme 
concentrations resulted in poor quality of the crystals as excepted from the results in BSC.  
 
Figure 5: Lysozyme concentrations for BOFC with 𝑥𝑥0 from 5 to 30 mm and 𝑓𝑓 from 0.1 to 1.0 Hz. 
Initial concentration of lysozyme solution was 50 mg/mL. 
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The concentration of crystallisation solution in BOFC decreased faster with an increase in 
amplitude or frequency for the same frequency or amplitude, respectively. There was a 
noticeable extent of variations of concentration profiles in BOFC, though no obvious trends of 
the variations among different oscillatory conditions were found. It should be noted that the 
variations seemed to be slightly higher at very weak and very intensive oscillatory conditions. 
Based on the experimental results of crystal quality and the concentration profiles in Figure 4 
and Figure 5, the 50 mg/mL lysozyme solution with 𝑥𝑥0 at 10 mm and 𝑓𝑓 at 0.5 Hz was found to 
be a suitable experimental condition to achieve the target continuous process with a 180 min 
residence time. 
 
Figure 6 Average lysozyme concentrations for initial lysozyme solution of 50 mg/mL at different 
mixing conditions (hence different 𝑅𝑅e) with crystallisation time (in BSC and BOFC) / resident 
time (in COFC) of 90 and 180 min. The straight solid and dashed lines are guiding lines for BSC 
and BOFC, respectively.  
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Continuous oscillatory flow crystallisation 
The net flow rate (Q) 0.1 mL/min was applied in the COFC, for a tube with four sample points, 
i.e. the mixing point and around 1, 2 and 3 m from the mixing point, with the optimised 
experimental condition from the COBC studies. The residence time of the lysozyme 
crystallisation solution in the COFC was 180 min by the designed Q, and, correspondingly, the 
solution taken from these four sample points had 0, 60, 120 and 180 min residence time, 
respectively, shown in Figure 7. As excepted, the lysozyme concentrations of the crystallisation 
solution was constant at the mixing point. The concentration of the crystallisation solution at 60 
min from the sample point two, 120 min from sample point 3 and 180 min from sample point 4 
in the COFC were consistent with the concentrations in BOFC (Figure 6) at respective residence 
time, demonstrating a successful process transfer from BOFC to COFC. These results were 
consistent with the literature on the nucleation of butyl paraben in batch and continuous 
OFC.23  
 
Figure 7 Lysozyme concentration at four sample points (0, 1, 2 and 3 m to the mixing point) for 
the COFC. 
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Figure 7 shows the longer the residence time of the crystallisation solution, the lower the 
concentration became and larger crystals were obtained. There were no crystals observed at 
the sample point one, and the crystals obtained from the last three sample points all had good 
crystal shapes. The size distributions were mainly normal distributions with a tiny peak at 
around 1 μm. The size distribution of crystals obtained from 180 - 270 min is very similar to 
those crystals from 270 - 360 min, while the later crystals were on average slightly larger with 
fewer fine particles, due to the lower concentration and longer growth time for the crystals at 
later stages. The similar size distributions with an average particle size of 11 – 12 μm and the 
concentrations indicate the steady state of the continuous crystallisation at each sample point 
after 180 min in COFC.  
 
Figure 8 Size distributions of lysozyme crystals obtained in the COFC and lysozyme crystal 
images in the sample solution from sample point three at 300 and 360 min, respectively, during 
the experiment. 
 
In Figure 9, a steeper slope corresponds to faster micrococcus lysodeikticus cells lysis and 
higher bioactivity of lysozyme per units volume solution.50 By using the same micrococcus 
lysodeikticus cells solution, the activity determination results show the activity of lysozyme 
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obtained from continuous oscillatory crystallisation was 20 % higher than the activity of the raw 
lysozyme materials, indicating the higher purity of lysozyme than the raw materials. This is an 
improvement in the quality of lysozyme as compared to the as-received material which was 
freeze-dried.  
 
Figure 9 Absorbance intensity at 450 nm of micrococcus lysodeikticus cells solution. Adding only 
buffer solution without lysozyme (rectangle symbol with black color), lysozyme of raw materials 
(round symbol with red color) and lysozyme obtained in COFC (triangle symbol with blue color ) 
in buffer solution. 
 
 
Discussions 
In this work, we focused on the development from Stage II to Stage IV utilising lysozyme as a 
model protein, due to the numerous studies reported for its crystallisation conditions in 
hanging drop experiments,24,40,58,59,65 and the availability of phase diagrams,24,58 bypassing Stage 
1. For other target proteins, however, the suitable crystallisation conditions may be unavailable 
and not easy to predict,6 i.e. it is still challenges to obtain single crystals of μm size for the 
structural determination of the target protein.66 In some cases, the suitable crystallisation 
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condition, which leads to a very slow crystallisation process (more than weeks), may greatly 
hinder the development at Stage II. 
 
The higher concentrations and higher share rate reduce the induction time and accelerate the 
crystallisation process, but it may lead to the formation of small crystals as shown in Figure 3, 
and induce different morphology as needle shape lysozyme reported,24 in agreement with the 
literature.40,67,68,69 It is preferable to test additional experimental conditions to determine 
kinetic parameters, at this stage, due to the ease of operations for the small volume tubes 
compared to the oscillatory flow crystalliser69 or other semi-continuous platforms.24 There were 
three periods of the changing concentration.69 As an example, for the crystallisation process 
with a shaking rate of 100 rpm, the conditions are: (A) an induction period (no decrease in 
concentration before nucleation), (B) a rapid concentration drop period, i.e. nucleation 
(homogeneous and secondary) and fast crystal growth at high supersaturation level and (C) a 
slow concentration decrease period, i.e. crystal growth at low supersaturation level. However, 
at very high concentration and high shaking rate, the A-period diminishes, and at low 
concentration with low shaking rate, the C-period was not clearly established during a period of 
180 minutes. Comparing with the crystallisation processes of many small-molecule70,71 with a 
sharp fall of the concentration after nucleation, the concentration decrease in many protein 
crystallisation is relative slow after nucleation17,39 due to high packing energy, low attachment 
frequency and slow kinetics of growth and etc.51 These periods influence the size distribution of 
the final crystal products by different mechanisms, like secondary nucleation or crystal growth, 
the mechanisms combined with simulations and process modelling need to be further 
investigated.  
 
The nucleation behaviour is also crucial in order to develop an understanding of the protein 
crystallisation process. The nucleation occurring was estimated by the sampling time when the 
average concentration reduced by 2% from the initial lysozyme concentration in crystallisation 
solution. The increase in the flow velocity of the solution generated by the syringes69, i.e. 4𝑥𝑥0𝑓𝑓, 
decreases the nucleation time as shown in Figure 10, for a crystallisation solution of the same 
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supersaturation. The shear, increasing with increase of velocity, accelerated the nucleation rate 
of lysozyme, which is consistent with the crystallisation of other proteins.3 Additionally, the 
control of the nucleation step with seeds or nano-templates is currently being investigated,52 in 
batch modes which can be useful for transfer to Stage IV. 
 
Figure 10 The average nucleation time of lysozyme solutions for the same oscillatory velocity of 
the solution in BOFC. Dashed line is a guiding line. 
 
In development stage IV, limited fouling in the oscillatory flow tube was observed along the 
tubing. It is heavier at the location near the mixing point where the supersaturation was 
significantly higher than further downstream locations. However, there was no blockage at the 
mixing point, due to the slow nucleation and crystal growth rate. There was no leaking and 
blockage in this work during the whole process. A drop of concentration at each sample point 
was observed after the initial crystallisation solution flow reached. This is because some 
lysozyme crystals formed after 30-60 min were trapped in the oscillatory flow between the 
oscillatory syringe and the net flow tube, which acted as seeds to the continuous oscillatory 
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flow solution in the crystallisation process. The seeding effect induced the concentration drop 
which was lower than the concentrations in respective residence time in the BOFC, and the 
concentrations reached an equilibrium after 180 min in these sample points. The trapped 
crystals, without resulting in blockage and leaking, may indicate the indicate the robustness of 
continuous crystallisation developed.    
 
The crystals obtained have limited agglomeration. The agglomerates break down after a very 
short sonication time, shown in the supporting information section. The yield in this COFC is ~ 
60 %, as estimated from the concentration determined at beginning (25 mg/mL) and the end of 
the crystallisation process (10 mg/mL). This yield is similar to the one reported in literature, 
where 68% of dissolved lysozyme was crystallised under slug flow with a resident time of 113 
minutes.39 Correspondingly, the space time yield is above 3.8 g/Lh. The yield can be improved 
by increasing the concentration of protein and precipitant, the residence time or the share rate, 
and can be further improved by decreasing the temperature.3,58 Varying process conditions and 
operating parameters can lead to an optimised continuous crystallisation process, whilst 
ensuring that the final crystal product meets quality, purity and bioactivity requirements.  
 
Conclusions 
In this work, we applied a basic workflow for the development of continuous oscillatory 
crystallisation process for a model protein, lysozyme from batch crystallisation. Four efficient 
steps to develop a continuous oscillatory flow crystallisation: 1). hanging-drop screening offers 
the suitable buffer, precipitant, pH and etc; 2). shaking batch crystallisation provides insight 
into basic kinetics and thermodynamics of the crystallisation; 3). batch oscillatory flow 
crystallisation offers more precise control of the protein concentration and mixing condition in 
the oscillatory flow; 4). continuous oscillatory flow crystallisation is finally established and 
further optimized, are reported. The higher concentration of lysozyme solution and higher 
frequency and amplitude in oscillatory flow enhanced the nucleation and crystallisation, leading 
to a reduction in the particle size and an increase in the number of the crystals. In the 
continuous oscillatory flow crystallisation, the concentration decreased with an increase in 
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residence time and steady stage was achieved. The lysozyme crystals obtained in this 
continuous crystallisation platform has a consistent size distribution. The lysozyme crystals 
obtained from this continuous oscillatory flow crystallization platform has both a good crystal 
shape and high bioactivity.  
 
 
Notations 
𝐶𝐶  Concentration of lysozyme solution (mg/mL) 
𝑑𝑑OFC Diameter of shaking tube  (m) 
𝑑𝑑SHC Diameter of oscillatory flow tube (m) 
𝑓𝑓 Frequency of oscillatory flow (Hz) 
𝑎𝑎 Shaking frequency (1/s) 
Q Net flow rate (mL/min) 
𝑅𝑅𝑒𝑒 Reynold's number  
𝑅𝑅𝑒𝑒[shaking]  Reynold's number in shaking tube  
𝑅𝑅𝑒𝑒[oscillation] Reynold's number in oscillatory flow   
𝑥𝑥0  Amplitude of oscillatory flow (mm) 
ρ Liquid density (kg/m) 
𝜋𝜋  3.1416  
𝜔𝜔  Shaking rate (rpm) 
𝜇𝜇  Dynamic fluid viscosity (mPa.s) 
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• A guiding workflow for developing continuous protein crystallisation 
• A successful development of continuous lysozyme crystallisation: micro L (hanging drop) 
→ mL (shaking platform) → 100 mL (oscillatory flow platform) 
• Good crystal shape and high bioactivity for product obtained in continuous crystallisation 
 
